US-based Syapse has formed a strategic alliance with Roche to accelerate product development and clinical delivery for offering precision medicine to more cancer patients and their healthcare providers.

As part of the multi-year collaboration, the firms will work towards the development of software products and analytics solutions to provide tools and insights required to practice precision medicine for enhancing outcomes and quality of life for patients.

The development will be sponsored by Roche, while Syapse will use its platform to develop and deploy the new products to the precision medicine ecosystem.

Syapse CEO Ken Tarkoff said: “Precision medicine is already improving cancer care, and Syapse is empowering healthcare providers with the tools they need to deliver the best possible care.

“By working together, Syapse and Roche can make this vision of precision medicine a reality faster than either of us could alone.”

“By working together, Syapse and Roche can make this vision of precision medicine a reality faster than either of us could alone.”

Initially, the project will see development of a learning health system of real-world evidence, integration of cancer care, analysis of electronic patient-reported outcomes and improved clinical trial enrolment.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The firms further plan to work on automated methods to measure real-world outcomes, and will consider other areas of collaboration with potential for precision medicine and better patient care.

Roche Pharmaceuticals CEO Daniel O’Day said: “Roche and Syapse share a common vision of ensuring widespread access to precision medicine so we can dramatically improve patient care. This collaboration supports that vision.

“By combining the pioneering platform from Syapse and Roche’s expertise in oncology, we can bring personalised healthcare to many more patients and healthcare providers.”